life scienc tool diagnost
confid valu proposit host investor meet evp
cfo jim cleari evp group presid bob mauch mid-west
manag emphas mission-crit role suppli
chain underscor recent strong broad-bas perform across core
busi dynam view underappreci make
chang estim rais tp
ebitda greater convict near term growth prospect
walk away meet increment optimist
solid core busi perform specialti driver strong alli
latest quarter exclud pharmedium setback benefit brazil
oper incom increas note strength specialti importantli
heighten industri focu specialti product develop
clinic perspect also fuel demand value-ad segment
servic ion lash world courier xcenda longer term mega trend
well-posit view leader specialti
success align strong anchor relationship mar
anim health florida cancer expand term volum
also encourag seemingli stabil drug price trend
offer element visibl near term
strong balanc sheet valuat reiter target
billion dilig capit deploy effort focus reinvest
busi commit dividend share repurchas
 continu evalu target near adjac includ
commerci provid servic well area anim
share trade ev/ebtida discount histor
averag view valuat attract maintain posit thesi
view better posit rel peer predic
driver larg custom relationship contribut non-cor
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global pharmaceut sourc
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
price jun rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
host investor meet evp cfo jim cleari evp group presid bob
mauch vice-president ir bennet murphi director ir dyisha reliford mid-west
maintain posit thesi view distributor better posit
rel peer predic driver larg custom relationship contribut
non-cor unit
last year oper incom grew msd exclud pharmedium headwind
latest quarter exclud pharmedium setback benefit brazil
oper incom increas particular strength specialti importantli
heighten focu specialti therapeut develop clinic perspect
also help fuel demand value-ad servic ion lash world courier
xcenda longer term mega trend well-posit view leader
specialti
also success align strong anchor relationship wba rad
asset marsvca banfield florida cancer expand term volum
success sap implement across core pharma unit allow swift
onboard new busi rite aid key custom account
current amidst sap implement across specialti unit
perform specialti distribut unit estimate revenu
standout grow dd recent strength across commun oncologist
over-index specialti physician practic importantli outsid core
distribut also highli lever broader specialti driver wraparound value-
ad servic provid manufactur provid alik ion busi
lead gpo commun oncologist market also offer critic
distribut servic manufactur world courier busi meanwhil
lash consult servic anoth value-add verifi patient benefit offer
adher data manufactur
biosimilar emerg biosimilar market progress glacial speed
prolifer new biosimilar repres potenti next wave growth
start see benefit quantifi biosimilar continu growth driver
sever year even without interchang albeit interchang would
posit dynam distributor note biosimilar altern sweet spot
term profit
gener deflat seemingli settl year vs histor smaller
headwind egregi deflat experienc past year fuel
prolifer me-too gener consequ fda effort acceler
gener approv overal encourag seemingli stabil gener
deflat trend offer element visibl
moreov remain hope commentari manufactur portfolio
optim lead stabil view market return mid-
single-digit deflat futur line histor trend
base proprietari analysi total gener drug sale report iqvia
highlight figur figur sell-sid averag sale price asp gener
therapeut rose weight sale averag april follow
increas weight sale march
weight
im trx top
drug
nadac data two month lag mean nadac releas may associ month march lag incorpor calcul
weight
refer tracker close repres sell side gener price util
iqvia sale databas report total purchas retail non-retail drug dispens
channel retail pharmaci facil mail-ord relev distribut channel
typic drug wholesal directli manufactur accord iqvia
dataset includ relev drug sale us importantli sale
figur correspond drug reflect invoic line item discount exampl volume-
relat discount dataset includ off-invoic discount prompt pay
importantli rebat paid directli manufactur custom insur
pbm use data track monthli asp gener drug exist
market place longer year divid total sale drug
associ total unit iqvia defin total manufactur ship packag
track year-over-year percentag chang price
still focu brand price inflat
note brand drug price inflat trend rel line
origin expect year estimate msd refer brand price inflat
becom recent concern given rhetor washington meaning lower
price increas sinc stabil light dynam view
street bake meaning lower brand price expect go-forward basi
brand price inflat still like headwind estimate msd vs hsd
previou year view larg bake
figur inflat exposur vs brand inflat expect distributor
percentag contract expos conting consider
vari view pos po rebat ultim
accomplish term influenc drug list price regardless view play role
help administ rebat pos potenti econom
disclos note administ similar autom discount class trade
outsid retail set well distributor larg
technolog place way facilit rebat admittedli
fundament remain strong across companion product anim busi
mix respect recent volatil us livestock market
leader recov come quarter consist commentari
industri constitu manag highlight strong relationship mar
primari distributor vca hospit well banfield largest veterinari
hospit chain us
recent onboard vca relationship year progress well
question recent chewi ipo remind mwi diversifi product
mix companion anim includ tradit pharma product vaccin parasiticid
suppli capit equip note mwi use particip distribut pet
food relationship hill ultim exit busi
manag reiter target billion dilig capit
deploy effort continu focu reinvest busi
commit dividend share repurchas million share
buyback past four quarter opportunist purchas continu
term continu evalu potenti target near adjac
exampl note commerci servic albeit multipl may lofti
provid servic well area anim similar recent allydvm
acquisit mwi broadli like pharma-centr diversif effort
would emphas prowess success acquir except
pharmediumwhich inconveni time recent year
note recent close small deal dymaxium announc may run
formularydecis com supplement xcenda consult busi detail
disclos contribut like de minimi
new meet
manag character enter consent decre may major
mileston full strateg evalu pharmedium busi howev still
progress weigh whether invest capit busi ration recent
cleveland ms facil closur divest time pharmedium acquisit
novemb admittedli expect regulatori environ evolv
quickli segment ultim held egregi manufactur
standard sterile-to-steril compound initi unanticip
histor context/timelin pharmedium
context product pharmedium memphi outsourc facil half
suspend complet remedi measur meanwhil three
pharmedium facil cover pharmedium fix cost indic
overal busi unit oper net loss therefor part comprehens
strateg financi review pharmedium decid close smallest
least-autom facil cleveland mississippi april consolid product
remain two open facil potenti improv profit profil albeit
continu engag cgmp expert consult firm support remedi
effort implement workforc reorgan strategi previous
emphas demand sterile-to-steril compound product would remain
healthi call right-siz expect note follow enhanc
qualiti assur qualiti control procedur well independ evalu
cgmp consult firm determin difficult
pharmedium overal volum return previou level next year
moreov enter consent decre may allow continu
commerci distribut two remain compound facil albeit
addit audit inspect requir least annual four year period
simultan conduct comprehens strateg financi review
busi could result invest busi
optim activ potenti sale busi intent
provid updat throughout year progress
remind acquir pharmedium novemb billion ad
largest independ provid compound steril prepar acut care
hospit us hospit custom time deal prior
recent complic highli profit busi growth impress clip
penetr exist custom custom addit
new meet much
continu vigor defend emphas make
chang report standard relev govern agenc relat opioid
view opioid continu overhang potenti limit capit
deploy driver emphas made chang capit alloc
remind opioid litig build overhang drug distributor
among industri constitu least opioid-rel case pend
lower court state albeit acknowledg case set court
date yet plaintiff counti state etc gener seem place blame
manufactur distributor claim misrepres risk opioid
usag fail properli monitor suspici order opioid respect
contribut broader epidem said nation drug distributor continu
defend posit note monitor capabl
view investor focu may intensifi approach upcom case includ
three consolid ohio lawsuit becom known bellweth test
case brought counti municip hospit other
thu far opioid-rel disclosur vari drug distributor though
constitu gener note higher expect litig expens
view continu ramp trial approach importantli cardin
includ litig cost sg potenti offset cost save initi
await updat upcom quarterli report
charl martineau pm univers toronto figur opioid litig tracker constitu
million litig cost primarili relat
opioid lawsuit investig
million litig cost primarili
relat opioid lawsuit relat initi
million litig cost primarili
relat opioid lawsuit
million litig cost primarili
relat opioid lawsuit
ny state opioid assess discuss
ny state opioid assess discuss
record million ny state opioid
million rever prior period assess
relat ny sate opioid stewardship act
litig expens quantifi
litig expens quantifi
ny stewardship act million
aggreg
litig expens quantifi
ny state opioid assess discuss
due uncertainti around ny state opioid
assess includ impact form
item assumpt
record million million
accru first half
relat ny opioid stewardship act
revers million accru
million accru first half
relat ny opioid stewardship act
litig expens quantifi
litig expens quantifi
ny state opioid assess discuss
ny state opioid assess discuss
record million expens relat
opioid impli million opioid litig
relat cost
record charg relat ny state opioid
stewardship act million impli
expens million expect opioid-
revers previous report charg
relat ny state opioid stewardship act
million litig cost primarili
relat opioid lawsuit
opioid-rel litig expens track
line prior guidanc fiscal year-to-d
realiz million cost
record million opioid litig
expens expect
million relat expens
figur opioid-rel report methodolog constitu
exclud ny state opioid stweardship act adjust result
includ litig cost sg
exclud ny state opioid stewardship act impact prior fiscal year adjust result
includ ny state opioid stewardship act impact current year period
includ litig cost sg
includ ny state opioid stewardship act iimpact adjust result
includ litig expens corpor segment adjust result
hd smith integr go well recent januari acquisit hd
smith achiev full run rate synergi
contract renew major contract renew loom come year
note fewer major contract renew lead distributor like help
enhanc visibl
amazon hard specul amazon next move manag emphas
complex suppli chain effort may consumer-ori
natur note amazon pillpack remain custom seen major
inflect growth trajectori unit
compani mention price
